Compugen Ltd. CGEN.TA Stock
Compugen Ltd. Price Chart
Compugen Ltd. CGEN.TA Financial and Trading Overview
Compugen Ltd. stock price | 792.4 ILA |
Previous Close | 499.3 ILA |
Open | 484 ILA |
Bid | 488.9 ILA x N/A |
Ask | 489 ILA x N/A |
Day's Range | 475 - 488 ILA |
52 Week Range | 209.4 - 799 ILA |
Volume | 101.15K ILA |
Avg. Volume | 113.6K ILA |
Market Cap | 411.47M ILA |
Beta (5Y Monthly) | 2.673239 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.79 ILA |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
CGEN.TA Valuation Measures
Enterprise Value | 359.99M ILA |
Trailing P/E | N/A |
Forward P/E | -8.189655 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 54.862247 |
Price/Book (mrq) | 594.4931 |
Enterprise Value/Revenue | 47.998 |
Enterprise Value/EBITDA | -10.278 |
Trading Information
Compugen Ltd. Stock Price History
Beta (5Y Monthly) | 2.673239 |
52-Week Change | -20.40% |
S&P500 52-Week Change | 20.43% |
52 Week High | 799 ILA |
52 Week Low | 209.4 ILA |
50-Day Moving Average | 302.1 ILA |
200-Day Moving Average | 307.6 ILA |
CGEN.TA Share Statistics
Avg. Volume (3 month) | 113.6K ILA |
Avg. Daily Volume (10-Days) | 141.91K ILA |
Shares Outstanding | 86.62M |
Float | 81.79M |
Short Ratio | N/A |
% Held by Insiders | 5.55% |
% Held by Institutions | 17.17% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -473.49% |
Gross Margin | 87.00% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -21.62% |
Return on Equity (ttm) | -39.82% |
Income Statement
Revenue (ttm) | 7.5M ILA |
Revenue Per Share (ttm) | 0.09 ILA |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | 6.53M ILA |
EBITDA | -35024752 ILA |
Net Income Avi to Common (ttm) | -33323000 ILA |
Diluted EPS (ttm) | -1.49 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 74.32M ILA |
Total Cash Per Share (mrq) | 0.86 ILA |
Total Debt (mrq) | 1.79M ILA |
Total Debt/Equity (mrq) | 2.59 ILA |
Current Ratio (mrq) | 7.131 |
Book Value Per Share (mrq) | 0.799 |
Cash Flow Statement
Operating Cash Flow (ttm) | N/A |
Levered Free Cash Flow (ttm) | N/A |
Profile of Compugen Ltd.
Country | Israel |
State | N/A |
City | Holon |
Address | Azrieli Center |
ZIP | 5885849 |
Phone | 972 3 765 8585 |
Website | https://cgen.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 69 |
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Q&A For Compugen Ltd. Stock
What is a current CGEN.TA stock price?
Compugen Ltd. CGEN.TA stock price today per share is 792.4 ILA.
How to purchase Compugen Ltd. stock?
You can buy CGEN.TA shares on the Tel Aviv exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Compugen Ltd.?
The stock symbol or ticker of Compugen Ltd. is CGEN.TA.
Which industry does the Compugen Ltd. company belong to?
The Compugen Ltd. industry is Biotechnology.
How many shares does Compugen Ltd. have in circulation?
The max supply of Compugen Ltd. shares is 953.94K.
What is Compugen Ltd. Price to Earnings Ratio (PE Ratio)?
Compugen Ltd. PE Ratio is now.
What was Compugen Ltd. earnings per share over the trailing 12 months (TTM)?
Compugen Ltd. EPS is -0.79 ILA over the trailing 12 months.
Which sector does the Compugen Ltd. company belong to?
The Compugen Ltd. sector is Healthcare.